Publications by authors named "Jorn Mulder"

Claim this Profile
A
A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach.
Jorn Mulder, Odile C van Stuijvenberg, Paula B van Hennik, Emile E Voest, Anna M G Pasmooij

Front Med (Lausanne)· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders.
Jorn Mulder, Robin Verjans, Ciska Verbaanderd, Elias Pean, Just Weemers

Front Med (Lausanne)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation.
Jorn Mulder, Tobias van Rossum, Segundo Mariz, Armando Magrelli, Anthonius de Boer

Front Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breakthrough therapy-designated oncology drugs: are they rightfully criticized?
Jorn Mulder, Anna M G Pasmooij, Violeta V Stoyanova-Beninska, Jan H M Schellens

Drug Discov Today· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects.
Luca Moscetti, Paula Hennik, Bjorg Bolstad, Jorge Camarero, Filip Josephson, Jorn Mulder

ESMO Open· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis